Compound Detail
CHEMBL940
GABAPENTIN 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL940 |
| Name | GABAPENTIN |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | UGJMXCAKCUNAIE-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
5
Targets
22
Activities
2
Assay Types
26
PK Parameters
20
Publications
11
Known Names
20
Indications
1
Mechanisms
Molecular Properties
171.2
MW (Da)
1.37
ALogP
2
HBA
2
HBD
63.3
PSA (Ų)
0.67
QED
0
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1993 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Voltage-gated calcium channel modulator | MODULATOR | Voltage-gated calcium channel | ✓ | ✓ |
Indications
Epilepsy Neuralgia, Postherpetic Neuralgia, Postherpetic Restless Legs Syndrome Seizures Alcohol Drinking Alcoholism Anxiety Azoospermia Brain Injuries Carpal Tunnel Syndrome Chronic Pain Cystitis, Interstitial Delirium Dementia Depressive Disorder Diabetic Neuropathies Dyspepsia Epilepsies, Partial Fibromyalgia
ATC Classification
N02BF01
gabapentin
Level 1: NERVOUS SYSTEM
Level 2: ANALGESICS
Activity Summary
IC50 19 meas. best 7.57
Ki 3 meas. best 6.92
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Voltage-dependent calcium channel subunit alpha-2/delta-1 CHEMBL1919 | IC50 | 7.57 | 7.57 | 27.0 | 1 |
| Voltage-dependent calcium channel alpha2delta subunit CHEMBL3985 | IC50 | 7.16 | 7.005 | 70.0 | 2 |
| Unchecked CHEMBL612545 | IC50 | 7.16 | 6.446 | 70.0 | 15 |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 CHEMBL4676 | Ki | 6.92 | 6.92 | 120.0 | 2 |
| Voltage-dependent calcium channel subunit alpha-2/delta-1 CHEMBL3420 | IC50 | 5.05 | 5.05 | 8900.0 | 1 |
| Unchecked CHEMBL612545 | Ki | 4.46 | 4.46 | 35000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 8600.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 8600.0 | ng.hr.mL-1 | Rattus norvegicus |
| CL | 6.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 6.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 1.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | - | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.8 | mL.min-1.kg-1 | Homo sapiens |
| CL | 2.3 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 2.6 | mL.min-1.kg-1 | Macaca |
| CL | 9.5 | mL.min-1.kg-1 | Rattus norvegicus |
| F | 76.0 | % | Rattus norvegicus |
| F | 60.0 | % | Homo sapiens |
| F | 76.0 | % | Rattus norvegicus |
| F | 25.0 | % | Macaca fascicularis |
| Fu | 0.97 | - | Homo sapiens |
| Fu | 0.97 | - | Homo sapiens |
| Fu | 1.0 | - | Rattus norvegicus |
| Fu | 1.06 | - | Rattus norvegicus |
| MRT | 7.0 | hr | Homo sapiens |
| T1/2 | 1.5 | hr | Rattus norvegicus |
| T1/2 | 1.5 | hr | Rattus norvegicus |
| T1/2 | 5.3 | hr | Homo sapiens |
| T1/2 | 5.0 | hr | Homo sapiens |
| Vd | 4.6 | L.kg-1 | Rattus norvegicus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine